aTyr Pharma GAAP EPS of -$0.26 misses by $0.08, revenue of $0.19M

* aTyr Pharma press release [https://seekingalpha.com/pr/20297760-atyr-pharma-announces-third-quarter-2025-results-and-provides-corporate-update] (ATYR [https://seekingalpha.com/symbol/ATYR]): Q3 GAAP EPS of -$0.26 misses by $0.08.
* Revenue of $0.19M.
* Cash & Investment Position: Cash, cash equivalents, restricted cash and available-for-sale investments as of September 30, 2025, were $92.9 million.

MORE ON ATYR PHARMA

* aTyr Pharma, Inc. (ATYR) Presents at The ERS Congress 2025 - Slideshow [https://seekingalpha.com/article/4827161-atyr-pharma-inc-atyr-presents-at-the-ers-congress-2025-slideshow]
* aTyr Pharma, Inc. (ATYR) Special Call - Slideshow [https://seekingalpha.com/article/4823180-atyr-pharma-inc-atyr-special-call-slideshow]
* aTyr Pharma: Moving To Hold On Release Of Pulmonary Sarcoidosis Treatment Data [https://seekingalpha.com/article/4823065-atyr-pharma-moving-to-hold-on-release-of-pulmonary-sarcoidosis-treatment-data]
* aTyr Pharma stock tanks after missing main goal in lung disease study [https://seekingalpha.com/news/4494854-atyr-pharma-stock-tanks-after-missing-main-goal-in-lung-disease-study]
* Seeking Alpha’s Quant Rating on aTyr Pharma [https://seekingalpha.com/symbol/ATYR/ratings/quant-ratings]